Latin America Aesthetic Injectables Market is expected to grow with the CAGR of 6.9% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.
Latin America aesthetic injectables market is a highly consolidated market which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.
The major players dealing in Latin America aesthetic injectables market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition and agreement into the market. This has helped the companies to maximize the sales with enhanced product portfolio. For instance, in November 2020, Galderma launched Dysport in China. It was used in the treatment of glabellar lines. Dysport had received the approval from National Medical Products Administration from China. This product launch has helped the company to highlight their dedication towards the aesthetic market and to introduce the novel product for the welfare of patients.
Allergan (a subsidiary of AbbVie Inc.) is the dominating player in Latin America aesthetic injectables market. The other key players existing in the aesthetic injectables Galderma, Laboratoires Vivacy, HUGEL, Inc., Merz Pharma, Anika Therapeutics, Inc., SKIN TECH PHARMA GROUP, Sinclair Pharma, Prollenium Medical Technologies, ADODERM GmbH, CROMA-PHARMA GmbH, BioScience GmbH, Contura Ltd., Suneva Medical, medyglobal among others.
Allergan (a subsidiary of AbbVie Inc.) is headquartered in Dublin, Ireland and was founded in 2013. The company is engaged on developing, manufacturing and marketing the pharmaceuticals, regenerative medical, surgical and biological products and devices for patients around the world. The company is providing products under categories such as central nervous system, eye care and gastroenterology, medical aesthetics, patient assistance programs and other products among which medical aesthetics is the market focused category. The company is taking various strategic initiatives in order to expand its business in the market.
The company has wide presence across North America, Asia-Pacific, Europe, Middle East and Africa and South America. The company has various subsidiaries such as ZELTIQ Aesthetics (U.S.), Actavis Group (U.S.), Kythera Biopharmaceuticals (U.S.), Tobira Therapeutics (U.S.), Bonti Inc (U.S.) among more.
Galderma is headquartered in La Tour-de-Peilz, Switzerland and was founded in 1981. The company focuses on skin products that help in protecting, providing nourishment and enhancing the quality of the skin. The company is providing products under categories namely prescription and aesthetics and consumer solutions out of which prescription and aesthetics is the market focused category. The company is engaged in receiving the product approvals.
The company has wide presence across Europe, Latin America, North America, Asia-Pacific and Middle East and Africa. The company also has various subsidiary companies such as Q-Med AB (Sweden), Galderma Laboratories L.P. (U.S.), G. Production (Canada), Q-Med International Limited (UAE) and Galderma Nordic AB (Sweden) among others.
Merz Pharma is headquartered in Frankfurt, Germany and was founded in 1908. The company is engaged on the health of the patient and help people to live a better life along with their better looks. The company is engaged in providing products under categories such as aesthetics and neurotoxins out of which aesthetics is the market focused category. The company has initiated many strategic initiatives to expand its market.
The company has wide presence across the U.S., Europe, Canada, Mexico, Brazil and Asia Pacific. The company has various subsidiary companies such as Merz Pharmaceuticals GmbH (Germany), Merz North America (United States), Anteis S.A (Switzerland), Merz Pharma France (France) among others.
Latin America Aesthetic Injectables Market – Industry Trends and Forecast to 2028